Navigation Links
Boston University Periodontal Study on Imagenetix Compound Published in The Journal of Periodontology
Date:8/12/2009

SAN DIEGO, Aug. 12 /PRNewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGX), announced today the publication of a second study conducted on its proprietary compound, 1-TDC, for the treatment of periodontal disease. Dr. Hatice Hasturk, D.D.S., Ph.D. from Boston University, Department of Periodontology and Oral Biology, led the investigative team. The study was published in the July issue of The Journal of Periodontology and is also available online at: http://www.joponline.org/loi/jop (J Periodontal 2009; 80(7):1103-13).

In the recent study, 1-TDC was applied to the gum line using the rabbit periodontitis model developed by Boston University investigators. The study results show that 1-TDC stopped the progression of periodontal disease with a significant improvement and restoration in tissue and bone health compared to the placebo group. "The results of this experiment are very exciting and demonstrate the great promise that 1-TDC offers in the treatment of periodontal disease," stated Dr. Hasturk. "These findings clearly demonstrate that 1-TDC reverses, at least in part, the damage associated with experimental periodontitis. We look forward to continuing our work with Imagenetix as they move towards the path of a new drug application (NDA) and progressive drug development with the FDA."

Commenting on the results of the study, Mr. William P. Spencer, President of Imagenetix said, "1-TDC is a promising early stage drug for the treatment of periodontitis. We now have two published animal studies showing clear evidence of efficacy and we continue to position our 1-TDC for a phase 1 trial with the FDA. In addition, we anticipate receiving news shortly on our patent associated with this compound. We also have contracted with an internationally respected Clinical Research Organization (CRO) to provide Imagenetix specific time lines to achieve drug approval from the FDA."

About Imagenetix

Imagenetix, based in San Diego, California, is an innovator of scientifically tested, natural-based, proprietary, bioceutical products developed to enhance human health on a global basis. Imagenetix develops and formulates propriety over-the-counter topical creams, skincare products and nutritional supplements to be marketed globally through multiple channels of distribution. In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners. Imagenetix is the creator of Inflame Away(R)-Celadrin(R). Please visit, www.celadrin.com or www.imagenetix.net.

Certain matters in this news release are forward-looking statements which are subject to risks and uncertainties that could cause actual results to vary materially from those projected. Such risks and uncertainties include, but are not limited to, adverse fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in the company's SEC filings, including its Form 10-K for the year ended March 31, 2009.

    Contact Imagenetix Investor Relations     William P. Spencer
            (858)385-2797                     Chief Executive Officer
                                              Imagenetix, Inc.
                                              Tel: (858) 674-8455


'/>"/>
SOURCE Imagenetix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Boston Scientific Announces European Approval for Its LATITUDE(R) Patient Management System
2. Boston Scientific to Participate in Wachovia Conference
3. Boston Scientifics SpyGlass(R) Direct Visualization System Featured in Broad Range of Clinical Studies at Upcoming Digestive Disease Week(R)
4. FDA Clears Boston Scientifics SpyScope(R) Access and Delivery Catheter for Use in Endoscopic Procedures Throughout Pancreatico-Biliary System
5. FDA Approves Boston Scientifics Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System
6. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
7. Boston Scientific Welcomes Launch of Syntax Score Website
8. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
9. Boston Scientific to Donate Cardiac Rhythm Management Devices to Heartbeat International for Implantation in Needy Patients
10. Boston Scientific Announces Company Schedule for Heart Rhythm Society Scientific Sessions
11. Xconomy Launches XSITE 2009; First Annual Xconomy Summit on Innovation, Technology, and Entrepreneurship at Boston University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... FireflySci cuvettes are used in leading laboratories all over the globe. Their ... , In addition to manufacturing awesome cuvettes, FireflySci makes spectrophotometer calibration standards that ...
(Date:5/25/2016)... ... May 25, 2016 , ... The ... by the Office of the National Coordinator for Health IT (ONC) outlining a ... clinically relevant data were available when and where it was needed. The organization ...
(Date:5/24/2016)... ... May 24, 2016 , ... Cell ... injuries, will be accelerated by research at Worcester Polytechnic Institute (WPI) that yielded ... healing and tissue regeneration. , The novel method, developed by WPI faculty members ...
(Date:5/23/2016)... , ... May 23, 2016 , ... ... Will Drive Precision Farming in 2017 and Beyond. The paper outlines the key ... the precision ag industry. , “We’ve witnessed a lot of highs and lows ...
Breaking Biology Technology:
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
Breaking Biology News(10 mins):